News Breaks |
|
|
| December 19, 2012 |
| 10:06 EDT |  | VRTX | Vertex INCIVEK sales likely to decline further, says Piper Jaffray
After the FDA forced Vertex to place a warning regarding fatal and non-fatal serious skin reactions on the boxes containing its INCIVEK HCV treatment, Piper Jaffray expects sales of the drug to decline further. The firm maintains a Neutral rating on the stock. |
|
|
News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks. |
|
|
| June 17, 2013 |
| 07:28 EDT |  | VRTX | Cambridge Healthtech Institute to host a conference
 Subscribe for More Information |
|
| June 14, 2013 |
| 09:38 EDT | | VRTX | Vertex has a conference call hosted by JPMorgan
Subscribe for More Information |
|
| 07:25 EDT | | VRTX | Vertex CF data positive, says RBC Capital
RBC Capital believes that data on Vertex's CF drug looked good and lowers the risk of the treatment. The firm expects the company to report good Phase III results for the drug in summer 2014, and it reiterates an Outperform rating on the stock. |
|
| June 12, 2013 |
| 07:33 EDT | | VRTX | European Cystic Fibrosis Society to host a conference
36th ECFS Conference is being held in Lisbon, Portugal on June 12-15. |
|
| June 11, 2013 |
| 14:37 EDT |  | VRTX | SMC posts decision on Kalydeco resubmission to website
Subscribe for More Information |
|
| 07:31 EDT | | VRTX | Goldman to host a conference
Subscribe for More Information |
|
| June 5, 2013 |
| 10:25 EDT | | VRTX | Vertex says 6 abstracts from cystic fibrosis program to be presented at ECFS
Subscribe for More Information |
|
|
|
|
|
